Triple threat: new combo shows promise for advanced lung cancer
Disease control
Completed
This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated advanced non-small cell lung cancer. The goal was to see if the combo could delay cancer growth and be safe. Results help guide future …
Phase: PHASE2 • Sponsor: Jeffrey Clarke • Aim: Disease control
Last updated May 14, 2026 12:03 UTC